| Issue Date |
Title |
Author(s) |
| 2015 |
Behavior Analysis through Collaborative Visual Exploration on Trajectory Data |
Ye, Tangzhi;Hao, Youfeng;Wang, Zhenhuang;Lai, Chufan;Chen, Siming;Li, Zongru;Liang, Jie;Yuan, Xiaoru |
| 2015 |
Behavior analysis through collaborative visual exploration on trajectory data |
Ye, Tangzhi;Hao, Youfeng;Wang, Zhenhuang;Lai, Chufan;Chen, Siming;Li, Zongru;Liang, Jie;Yuan, Xiaoru |
| 15-Nov-2022 |
Cancer-Related Gene Mutations Drive Resistance to the Third-Generation Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia |
Zhang, Xiaoshuai;Li, Zongru;Qin, Ya-Zhen;Gale, Robert Peter;Lai, Yueyun;Shi, Hongxia;Huang, Xiao Jun;Jiang, Qian |
| 16-Mar-2021 |
Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody |
Sun, Xin;Peng, Min;Zhang, Ting;Li, Zongru;Song, Lan;Li, Mengtao;Shi, Juhong |
| 23-Nov-2021 |
Correlations between Mutations in Cancer -Related Genes, Therapy Responses and Outcomes of the 3 (rd) Generation Tyrosine Kinase-Inhibitor (TKI) in Persons with Chronic Myeloid Leukemia Failing Prior TKI-Therapy |
Zhang, Xiaoshuai;Li, Zongru;Qin, Yazhen;Gale, Robert Peter;Huang, Xiaojun;Jiang, Qian |
| 15-Nov-2022 |
A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China |
Jiang, Qian;Li, Zongru;Qin, Ya-Zhen;Zhao, Ting;Liu, Bingcheng;Chen, Zi;Niu, Qian;Men, Lichuang;Wang, Hengbang;Yang, Dajun;Zhai, Yifan;Huang, Xiao-Jun |
| Jan-2022 |
Integrated genomic analyses identify high-risk factors and actionable targets in T-cell acute lymphoblastic leukemia |
Zhu, Haichuan;Dong, Bingjie;Zhang, Yingchi;Wang, Mei;Rao, Jianan;Cui, Bowen;Liu, Yu;Jiang, Qian;Wang, Weitao;Yang, Lu;Yu, Anqi;Li, Zongru;Liu, Chao;Zhang, Leping;Huang, Xiaojun;Zhu, Xiaofan;Wu, Hong |
| 2017 |
Interaction plus : Interaction Enhancement for Web-based Visualizations |
Lu, Min;Liang, Jie;Zhang, Yu;Li, Guozheng;Chen, Siming;Li, Zongru;Yuan, Xiaoru |
| 2017 |
Interaction+: Interaction enhancement for web-based visualizations |
Lu, Min;Liang, Jie;Zhang, Yu;Li, Guozheng;Chen, Siming;Li, Zongru;Yuan, Xiaoru |
| May-2022 |
Lower tumor burden is associated with better cognitive function in patients with chronic phase chronic myeloid leukemia |
Li, Zongru;Peng, Li;Li, Yongjie;Zhang, Jun;Jiang, Qian |
| 8-Jun-2021 |
Mental Health in Persons With Chronic Myeloid Leukemia During the SARS-CoV-2 Pandemic: The Need for Increased Access to Health Care Services |
Bao, Mei;Yang, Sen;Gale, Robert Peter;Zhang, Yanli;Liu, Xiaoli;Zhu, Huanling;Liang, Rong;Liu, Bingcheng;Zhou, Li;Li, Zongru;Dou, Xuelin;Shi, Dayu;Wang, Tao;Meng, Li;Li, Weiming;Jiang, Qian |
| Jun-2020 |
Monosomal karyotype is associated with poor outcomes in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia receiving chemotherapy but not allogeneic hematopoietic stem cell transplantation |
Li, Zongru;Lai, Yueyun;Zhang, Xiaohui;Xu, Lanping;Liu, Kaiyan;Wang, Yu;Yan, Chenhua;Jiang, Hao;Huang, Xiaojun;Jiang, Qian |
| 18-Aug-2022 |
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial |
Jiang, Qian;Li, Zongru;Qin, Yazhen;Li, Weiming;Xu, Na;Liu, Bingcheng;Zhang, Yanli;Meng, Li;Zhu, Huanling;Du, Xin;Chen, Suning;Liang, Yang;Hu, Yu;Liu, Xiaoli;Song, Yongping;Men, Lichuang;Chen, Zi;Niu, Qian;Wang, Hengbang;Lu, Ming;Yang, Dajun;Zhai, Yifan;Huang, Xiaojun |
| 31-Oct-2022 |
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial (vol 15, 113, 2022) |
Jiang, Qian;Li, Zongru;Qin, Yazhen;Li, Weiming;Xu, Na;Liu, Bingcheng;Zhang, Yanli;Meng, Li;Zhu, Huanling;Du, Xin;Chen, Suning;Liang, Yang;Hu, Yu;Liu, Xiaoli;Song, Yongping;Men, Lichuang;Chen, Zi;Niu, Qian;Wang, Hengbang;Lu, Ming;Yang, Dajun;Zhai, Yifan;Huang, Xiaojun |
| 20-Feb-2023 |
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial (vol 15, 159, 2022) |
Jiang, Qian;Li, Zongru;Qin, Yazhen;Li, Weiming;Xu, Na;Liu, Bingcheng;Zhang, Yanli;Meng, Li;Zhu, Huanling;Du, Xin;Chen, Suning;Liang, Yang;Hu, Yu;Liu, Xiaoli;Song, Yongping;Men, Lichuang;Chen, Zi;Niu, Qian;Wang, Hengbang;Lu, Ming;Yang, Dajun;Zhai, Yifan;Huang, Xiaojun |
| 23-Nov-2021 |
Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 (T315I)-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) |
Qian, Jiang;Shi, Dayu;Li, Zongru;Hou, Yue;Hu, Yu;Li, Weiming;Liu, Xiaoli;Xu, Na;Song, Yongping;Zhang, Gongli;Meng, Li;Hong, Zhenya;Liu, Bingcheng;Li, Yan;Chen, Suning;Xue, Mengxing;Zhu, Huanling;Li, He;Du, Xin;Lou, Jin;Zhang, Xiaohan;Liang, Yang;Dai, Yujun;Chen, Zi;Niu, Qian;Men, Lichuang;Yang, Dajun;Zhai, Yifan;Huang, Xiaojun |
| 15-Nov-2022 |
Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation |
Jiang, Qian;Li, Zongru;Hou, Yue;Hu, Yu;Li, Weiming;Liu, Xiaoli;Xu, Na;Zhang, Yanli;Song, Yongping;Meng, Li;Hong, Zhenya;Liu, Bingcheng;Li, Yan;Chen, Suning;Xue, Mengxing;Zhu, Huanling;Li, He;Du, Xin;Lou, Jin;Zhang, Xiaohan;Liang, Yang;Dai, Yu-Jun;Chen, Zi;Niu, Qian;Men, Lichuang;Yang, Dajun;Zhai, Yifan;Huang, Xiao-Jun |
| 23-Nov-2021 |
Updated Safety and Efficacy Results of Phase 1 Study of Olverembatinib (HQP1351), a Novel Third -Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) |
Qian, Jiang;Shi, Dayu;Li, Zongru;Qin, Yazhen;Zhao, Ting;Liu, Bingcheng;Chen, Zi;Niu, Qian;Men, Lichuang;Wang, Hengbang;Yang, Dajun;Zhai, Yifan;Huan, Xiaojun |
| Nov-2020 |
Variables associated with self-reported anxiety and depression symptoms in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy |
Shi, Dayu;Li, Zongru;Li, Yongjie;Jiang, Qian |
